Decision on PGR: Nov 19, 2018
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Status
|
|
PGR2018-00059
|
04/02/2018
|
10/10/2018
|
Alnylam
Pharmaceuticals, Inc.
|
9,695,423
|
Silence
Therapeutics GMBH
|
Terminated-Settled
|
|
PGR2018-00067
|
06/11/2018
|
--
|
Alnylam
Pharmaceuticals, Inc.
|
9,758,784
|
Silence
Therapeutics GMBH
|
Terminated-Settled
|
US 9,695,423 (Silence Therapeutics GMBH; Exp: Aug 05, 2023*TD):
1. A double-stranded siRNA molecule wherein: (i) at least
one strand of the double-stranded siRNA molecule comprises one or more groups
of modified nucleotides and one or more groups of flanking nucleotides, the
flanking nucleotides being on one or both sides of the modified nucleotides,
wherein: the one or more groups of modified nucleotides have an amino, fluoro,
alkoxy, or alkyl modification at the 2'-position; and the one or more groups of
flanking nucleotides have an amino, fluoro, alkoxy, or alkyl modification at
the 2'-position, the modification at the 2'-position of the flanking nucleotide
being different from the modification at the 2'-position of the modified
nucleotide, (ii) the number of nucleotides in the one or more groups of
modified nucleotides is 1-10 and the number of nucleotides in the one or more
groups of flanking nucleotides is 1-10; (iii) the double-stranded siRNA
molecule has a double-stranded region of 17-21 nucleotides in length; and (iv)
the double-stranded siRNA molecule is capable of RNA interference.
12. A double-stranded siRNA molecule wherein: (i) each
strand of the double-stranded siRNA molecule comprises one or more groups of
modified nucleotides and one or more groups of flanking nucleotides, the
flanking nucleotides being on one or both sides of the modified nucleotides,
wherein the one or more groups of modified nucleotides have an amino, fluoro,
alkoxy, or alkyl modification at the 2'-position; and the one or more groups of
flanking nucleotides have an amino, fluoro, alkoxy, or alkyl modification at
the 2'-position, the modification at the 2'-position of the flanking nucleotide
being different from the modification at the 2'-position of the modified
nucleotide, (ii) the number of nucleotides in the one or more groups of
modified nucleotides is 1-10 and the number of nucleotides in the one or more
groups of flanking nucleotides is 1-10; (iii) the double-stranded siRNA
molecule has a double-stranded region of 17-21 nucleotides in length; and (iv)
the double-stranded siRNA molecule is capable of RNA interference.
US 9,758,784 (Silence Therapeutics GMBH; Exp: Aug 05, 2023*TD):
1. A double-stranded siRNA molecule against a target nucleic
acid, wherein the double-stranded siRNA molecule comprises a first strand and a
second strand, wherein the first strand comprises a first stretch that is
complementary to the target nucleic acid, wherein the second strand comprises a
second stretch that is complementary to the first stretch, wherein the first
strand and the second strand form a double-stranded structure comprising the
first stretch and the second stretch, wherein the double-stranded siRNA
molecule is blunt ended on at least one end, and wherein each stretch consists
of at least 15 and fewer than 30 ribonucleotides and wherein the first stretch
and the second stretch each comprises contiguous alternating modified
ribonucleotides, wherein the alternating modified ribonucleotides alternate
with unmodified or differently modified ribonucleotides.
Both the parties have also settled their dispute in EU &
worldwide. See below press release for more information.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 10, 2018-- Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company,
announced today that it has resolved all litigation worldwide with Silence
Therapeutics. The settlement allows Alnylam to avoid the costs and distraction
associated with continued litigation in multiple countries. Under terms of the
global settlement, Silence will receive a low royalty on annual net sales of
ONPATTRO in the EU only, with tiered royalties of 0.33 percent to 1.0 percent
through 2023.
No comments:
Post a Comment